Q-linea AB (publ) (STO:QLINEA)

Market Cap	346.76M +116.6%
Revenue (ttm)	11.81M +62.0%
Net Income	-170.83M
EPS	-15.76
Shares Out	18.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,397
Average Volume	13,598
Open	16.60
Previous Close	16.90
Day's Range	16.50 - 18.40
52-Week Range	14.55 - 79.00
Beta	0.54
RSI	51.33
Earnings Date	Jul 10, 2026

About Q-linea AB

Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood cult...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2007
• Employees: 82
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: QLINEA

Financial Performance

In 2025, Q-linea AB's revenue was 15.29 million, an increase of 269.29% compared to the previous year's 4.14 million. Losses were -182.49 million, -15.86% less than in 2024.